OptiBiotix Health (LON:OPTI) Announces Earnings Results

OptiBiotix Health (LON:OPTI) posted its earnings results on Thursday. The company reported GBX (3.84) earnings per share for the quarter, Digital Look Earnings reports. The firm had revenue of GBX 117 million during the quarter. OptiBiotix Health had a negative net margin of 333.62% and a negative return on equity of 52.92%.

OptiBiotix Health Price Performance

LON:OPTI opened at GBX 6.06 on Friday. The company’s 50-day moving average is GBX 5.31 and its two-hundred day moving average is GBX 6.35. OptiBiotix Health has a 1-year low of GBX 4.50 and a 1-year high of GBX 15. The firm has a market capitalization of £6.26 million, a price-to-earnings ratio of -202.00 and a beta of 1.71.

Insiders Place Their Bets

In related news, insider David Blain bought 158,965 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was purchased at an average price of GBX 6 per share, for a total transaction of £9,537.90. Company insiders own 26.82% of the company’s stock.

About OptiBiotix Health

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome – the collective genome of the microbes in the body – in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products.